# What Semaglutide Doses Did Danish Pharmacy Users Report? | Buy This GLP

In a survey of 767 Danish semaglutide users, 45% were on 1 mg and 8% expected to reach 2.4 mg, while 10% reported dosing by counting clicks on the pen.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/what-dose-do-most-people-actually-reach
Updated: 2026-11-14
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# What Semaglutide Doses Did Danish Pharmacy Users Report?

In a Danish pharmacy survey, 45% of respondents reported taking 1 mg of semaglutide and 8% expected to reach 2.4 mg.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

Danish pharmacy survey, 767 people buying semaglutide · currently on 1 mg · 45% · expect to reach 2.4 mg · 8% · Current doses and future expectations were self-reported. · And 10% said they dose by counting clicks on the pen.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A survey at 28 Danish community pharmacies collected responses from 767 of 1,470 adults redeeming a semaglutide weight-management prescription.
-   Forty-five percent were currently taking 1 mg, and only 8% expected ever to reach the 2.4 mg label dose for weight management.
-   Ten percent reported dosing by counting clicks on the injection pen, against official prescribing guidance.
-   Self-reported weight loss among 1 mg users was similar to the cohort overall at each treatment duration.

Well below the label dose. In a survey of 767 Danish adults collecting a semaglutide weight-management prescription, 45% were currently taking 1 mg and only 8% expected ever to reach the 2.4 mg label dose. Ten percent reported dosing by counting clicks on the pen, against official prescribing guidance.

A separate [study of tirzepatide refills](https://buythisglp.com/research/tirzepatide-most-never-reach-ten) reported that most participants were still below 10 mg at the sixth fill [\[2\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-2). For either drug, compare the total at your prescribed dose and ask what would change if your prescriber adjusts it.

The [single-practice semaglutide study](https://buythisglp.com/research/what-semaglutide-dose-do-people-stay-on) tracked doses and treatment interruptions over time. This pharmacy survey asked 767 respondents what they took and what they expected to take. About 45% reported taking 1 mg at the time of the survey, and 8% expected to reach 2.4 mg [\[1\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-1).

At one to three months, the median self-reported weight loss was 6% (IQR 3% to 7%). Beyond a year, it was 20% (IQR 15% to 26%). Median loss was 12% at three to six months and 17% at six to twelve months [\[1\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-1). Among people on 1 mg the figures were similar. The survey did not assign doses or compare their effects under controlled conditions. A [randomized tirzepatide maintenance trial](https://buythisglp.com/research/can-you-lower-your-glp1-dose-to-maintain) compared continuing treatment, lowering the dose and switching to placebo after initial weight loss. Its results apply to the specific tirzepatide regimens studied.

This is a snapshot, not a curve

The duration groups contain different respondents. People who had already stopped treatment are less likely to appear in a survey of people collecting a prescription. The longer-duration figures describe those respondents at the time of the survey.

Ten percent reported counting clicks on their injection pen, a practice the authors say differs from official instructions [\[1\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-1). The survey did not verify the amount those respondents injected.

Twenty-four percent reported reducing or stopping another medication after starting semaglutide [\[1\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-1). Common categories among those reporting changes included medications for muscle or joint pain (30%) and blood pressure (24%). The survey recorded changes reported by patients. It did not measure prescription savings.

Among 42 first-time users in a separate six-month follow-up, 83% reported still using semaglutide [\[1\]](https://buythisglp.com/research/what-dose-do-most-people-actually-reach#ref-1). The [guide to prepaying for a GLP-1](https://buythisglp.com/research/should-you-prepay-for-a-glp1) uses larger studies to put treatment discontinuation in context. Before paying for six months, check the refund terms if you stop early.

## Frequently asked

What dose are most people actually on?

In this survey, 45% were taking 1 mg and only 8% expected ever to reach the 2.4 mg weight-management dose. Self-reported results among 1 mg users were similar to the cohort overall.

Do the weight loss figures show what happens over a year?

No. They come from different people answering at one point in time, so the longer-duration figures describe people who were still taking the drug — not a group followed from the start.

Did people stop other medications?

Twenty-four percent reported reducing or discontinuing another medication, most often for muscle or joint pain (30%) and blood pressure (24%).

## Sources

1.  \[1\] Kjærgaard K, Graabæk T, Thomsen RW, Cardél LG, Bramming M, Pottegård A, Lundby C (2026). Treatment Patterns and Experienced Effects of Semaglutide for Weight Management Among Adult Users in Denmark: A Community Pharmacy-Based Cross-Sectional Survey Diabetes, Obesity and Metabolism. [PMID 42443134](https://pubmed.ncbi.nlm.nih.gov/42443134/)
2.  \[2\] Hankosky ER, et al. (2025). Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database Diabetes, Obesity and Metabolism. [PMID 39996368](https://pubmed.ncbi.nlm.nih.gov/39996368/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
